Direct Xa inhibitor

Direct Xa inhibitor is a type of anticoagulant that works by inhibiting the activity of Factor Xa, an enzyme that plays a crucial role in blood clotting. These inhibitors are used in the prevention and treatment of conditions such as deep vein thrombosis and pulmonary embolism, and in patients with atrial fibrillation to reduce the risk of stroke.

Mechanism of Action[edit | edit source]

Direct Xa inhibitors work by directly binding to Factor Xa, thereby inhibiting its ability to convert prothrombin into thrombin, a key enzyme in the blood clotting process. This prevents the formation of fibrin, the main component of blood clots.

Uses[edit | edit source]

Direct Xa inhibitors are used in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. They are also used in patients with atrial fibrillation, a heart condition that increases the risk of stroke, to reduce this risk.

Examples[edit | edit source]

Examples of Direct Xa inhibitors include rivaroxaban, apixaban, and edoxaban. These drugs are taken orally and do not require regular blood monitoring, unlike warfarin, a vitamin K antagonist anticoagulant.

Side Effects[edit | edit source]

Common side effects of Direct Xa inhibitors include bleeding, anemia, and gastrointestinal disturbances. In rare cases, they can cause serious bleeding complications.

Contraindications[edit | edit source]

Direct Xa inhibitors are contraindicated in patients with severe renal impairment, liver disease, or active bleeding. They should also be used with caution in patients taking other medications that increase the risk of bleeding.